Aqua Bio Technology (OSL: ABTEC) financial statements
The consolidated income statement, balance sheet and cash flow statement of Aqua Bio Technology for its last 6 fiscal years, as filed with the regulator, in millions of Norwegian kroner. At the end of fiscal 2025 it had NOK 130.0m in total assets and −NOK 0.5m in equity.
Income statement
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | NOK 1.3m | NOK 106.6m | NOK 18.4m | NOK 7.0m | NOK 1.6m | NOK 0.4m |
| Operating profit | −NOK 11.7m | −NOK 325.7m | −NOK 15.8m | −NOK 16.4m | −NOK 17.9m | −NOK 16.1m |
| Finance costs | NOK 12.2m | NOK 20.0m | NOK 5.2m | NOK 2.5m | NOK 1.6m | NOK 0.3m |
| Profit before tax | −NOK 24.6m | −NOK 345.2m | −NOK 20.8m | −NOK 18.8m | −NOK 19.1m | −NOK 15.0m |
| Income tax | NOK 0.0m | −NOK 7.8m | NOK 0.2m | −NOK 0.0m | NOK 0.0m | −NOK 0.2m |
| Net profit | NOK 97.7m | −NOK 337.4m | −NOK 21.0m | −NOK 18.7m | −NOK 19.1m | −NOK 14.7m |
| Earnings per share | NOK 38.60 | — | — | −NOK 0.91 | −NOK 0.99 | — |
| Diluted earnings per share | NOK 38.60 | — | — | −NOK 0.92 | −NOK 0.99 | — |
| Depreciation and amortisation | NOK 1.0m | NOK 11.7m | NOK 3.7m | NOK 1.7m | NOK 1.1m | NOK 0.1m |
Balance sheet
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total assets | NOK 130.0m | NOK 249.7m | NOK 237.7m | NOK 67.2m | NOK 34.4m | NOK 16.2m |
| Current assets | NOK 3.3m | NOK 37.6m | NOK 48.8m | NOK 12.8m | NOK 21.9m | NOK 6.4m |
| Inventories | NOK 0.0m | NOK 5.5m | NOK 23.9m | NOK 8.3m | NOK 5.7m | NOK 0.8m |
| Property, plant and equipment | NOK 0.0m | NOK 0.7m | NOK 5.1m | NOK 0.1m | NOK 0.3m | NOK 0.5m |
| Goodwill | NOK 0.0m | NOK 75.2m | NOK 123.5m | NOK 34.7m | — | — |
| Cash | NOK 2.7m | NOK 17.2m | NOK 4.8m | NOK 1.9m | NOK 13.4m | NOK 5.4m |
| Total liabilities | NOK 130.5m | NOK 331.4m | NOK 152.0m | NOK 65.3m | NOK 15.7m | NOK 7.9m |
| Current liabilities | NOK 129.6m | NOK 198.7m | NOK 119.5m | NOK 24.8m | NOK 12.1m | NOK 3.3m |
| Equity | −NOK 0.5m | −NOK 81.7m | NOK 85.8m | NOK 1.9m | NOK 18.7m | NOK 8.3m |
| Equity including minorities | −NOK 0.5m | −NOK 81.7m | NOK 85.8m | NOK 1.9m | NOK 18.7m | NOK 8.3m |
Cash flow statement
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | −NOK 8.2m | −NOK 46.9m | −NOK 19.3m | −NOK 15.4m | −NOK 21.0m | −NOK 13.3m |
| Investing cash flow | NOK 0.5m | NOK 13.0m | −NOK 1.4m | −NOK 4.1m | −NOK 5.4m | −NOK 3.3m |
| Financing cash flow | NOK 4.3m | NOK 46.2m | NOK 23.7m | NOK 8.0m | NOK 34.3m | NOK 15.2m |
Where each figure comes from
From the annual report Aqua Bio Technology files every year in the European single electronic format (ESEF). The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021. If an item is not tagged in the filing, it is not in the table. The summary of the last fiscal year is on the Aqua Bio Technology page.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.